MX2018000542A - Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. - Google Patents
Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.Info
- Publication number
- MX2018000542A MX2018000542A MX2018000542A MX2018000542A MX2018000542A MX 2018000542 A MX2018000542 A MX 2018000542A MX 2018000542 A MX2018000542 A MX 2018000542A MX 2018000542 A MX2018000542 A MX 2018000542A MX 2018000542 A MX2018000542 A MX 2018000542A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- receptor
- peptide inhibitors
- inflammatory diseases
- treat inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 | |
| PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018000542A true MX2018000542A (es) | 2018-06-27 |
Family
ID=57757647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000542A MX2018000542A (es) | 2015-07-15 | 2016-07-15 | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (ru) |
| JP (1) | JP6858174B2 (ru) |
| KR (1) | KR102513978B1 (ru) |
| CN (1) | CN108348580B (ru) |
| AU (1) | AU2016293619B2 (ru) |
| BR (1) | BR112018000691A2 (ru) |
| CA (1) | CA2991984A1 (ru) |
| CL (3) | CL2018000128A1 (ru) |
| CO (1) | CO2018000349A2 (ru) |
| CR (1) | CR20180029A (ru) |
| DO (1) | DOP2018000010A (ru) |
| EA (1) | EA035733B9 (ru) |
| EC (1) | ECSP18002929A (ru) |
| HK (2) | HK1257747A1 (ru) |
| IL (1) | IL256827A (ru) |
| MX (1) | MX2018000542A (ru) |
| NI (1) | NI201800008A (ru) |
| PE (1) | PE20180571A1 (ru) |
| PH (1) | PH12018500086A1 (ru) |
| SG (1) | SG10201912066SA (ru) |
| SV (1) | SV2018005614A (ru) |
| UA (1) | UA123772C2 (ru) |
| WO (1) | WO2017011820A2 (ru) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
| TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| KR20230036156A (ko) | 2014-05-16 | 2023-03-14 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | α4β7 인테그린 티오에테르 펩티드 길항제 |
| RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
| AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS |
| EP3570864A4 (en) * | 2017-01-18 | 2020-12-30 | Protagonist Therapeutics, Inc. | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE IN THE TREATMENT OF FLAMMABLE DISEASES |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
| TW202019948A (zh) * | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN110015978B (zh) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3997105A4 (en) * | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES |
| TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL294680A (en) | 2020-01-15 | 2022-09-01 | Janssen Biotech Inc | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| KR20220141808A (ko) | 2020-01-15 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도 |
| PE20240631A1 (es) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023288017A2 (en) * | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Bicyclic peptide inhibitors of interleukin-23 receptor |
| WO2023099669A1 (en) | 2021-12-01 | 2023-06-08 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (zh) * | 2022-03-17 | 2023-11-07 | 北京大学 | 订书肽、其制备方法及其制药用途 |
| WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| WO2009007849A2 (en) * | 2007-07-06 | 2009-01-15 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US10416172B2 (en) | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| EP3065757A4 (en) * | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| RU2736637C9 (ru) * | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
-
2016
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/ja active Active
- 2016-07-15 EA EA201890325A patent/EA035733B9/ru not_active IP Right Cessation
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/es unknown
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/zh active Active
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/ko active IP Right Grant
- 2016-07-15 CR CR20180029A patent/CR20180029A/es unknown
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/es unknown
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
- 2016-07-15 UA UAA201801482A patent/UA123772C2/uk unknown
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/pt active Search and Examination
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/es unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/es unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/es unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/es unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/es unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/es unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/es unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/zh unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/zh unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500086A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MD3360558T2 (ro) | Compoziții care cuprind tulpini bacteriene | |
| MX2023008693A (es) | Polinucleotidos moduladores. | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MD3204025T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| MD3650033T2 (ro) | Compoziții conţinând tulpini bacteriene | |
| EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| MX2020011749A (es) | Composiciones y metodos para modular la expresion de pkk. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2022000397A (es) | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| MX2020011668A (es) | Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EA201791937A1 (ru) | Противовоспалительные полипептиды | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases |